Cargando…
Cytotoxic Chemotherapy as an Alternative for Systemic Treatment of Advanced Hepatocellular Carcinoma in Developing Countries
Systemic therapy options nowadays for advanced hepatocellular carcinoma (HCC) are either immunotherapy with immune checkpoint inhibitors or targeted therapy. As the incidence of liver cancer is much higher in developing countries, these new medications are not readily accessible for most of the pati...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7707432/ https://www.ncbi.nlm.nih.gov/pubmed/33273860 http://dx.doi.org/10.2147/CMAR.S280631 |
_version_ | 1783617346069331968 |
---|---|
author | Abouelezz, Khaled Khanapara, Dipen Batiha, Gaber El-Saber Ahmed, Esraa A Hetta, Helal F |
author_facet | Abouelezz, Khaled Khanapara, Dipen Batiha, Gaber El-Saber Ahmed, Esraa A Hetta, Helal F |
author_sort | Abouelezz, Khaled |
collection | PubMed |
description | Systemic therapy options nowadays for advanced hepatocellular carcinoma (HCC) are either immunotherapy with immune checkpoint inhibitors or targeted therapy. As the incidence of liver cancer is much higher in developing countries, these new medications are not readily accessible for most of the patients. Cytotoxic chemotherapy agents are more available and affordable in developing countries. We are trying to explore the effectiveness of the newer cytotoxic agents in the systematic treatment for advanced HCC. This is a systematic review of all randomized controlled trials since 1997 that utilized systemic cytotoxic chemotherapy agents in the systemic treatment for advanced HCC using Scopus, PubMed, and Cochrane library up to February 2020. Six randomized trials were found. Different drugs and dosages were used, so it was statistically inappropriate to conduct a meta-analysis. No Phase III trial showed statistically significant overall survival (OS) benefit for cytotoxic chemotherapy, except subgroup analysis of Chinese patients in one study who had leucovorin, fluorouracil, and oxaliplatin (FOLFOX) regimen. There was no significant progression-free survival (PFS) or response rate in the Phase II trials. There are not enough data to infer the actual benefits of systemic cytotoxic chemotherapy in advanced HCC. However, oxaliplatin-based regimens may give feasible results. Health systems with limited access to targeted therapy and immunotherapy agents may use oxaliplatin-based regimens in clinical trials for advanced HCC. These results should be confirmed in multiple future randomized clinical trials. |
format | Online Article Text |
id | pubmed-7707432 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-77074322020-12-02 Cytotoxic Chemotherapy as an Alternative for Systemic Treatment of Advanced Hepatocellular Carcinoma in Developing Countries Abouelezz, Khaled Khanapara, Dipen Batiha, Gaber El-Saber Ahmed, Esraa A Hetta, Helal F Cancer Manag Res Review Systemic therapy options nowadays for advanced hepatocellular carcinoma (HCC) are either immunotherapy with immune checkpoint inhibitors or targeted therapy. As the incidence of liver cancer is much higher in developing countries, these new medications are not readily accessible for most of the patients. Cytotoxic chemotherapy agents are more available and affordable in developing countries. We are trying to explore the effectiveness of the newer cytotoxic agents in the systematic treatment for advanced HCC. This is a systematic review of all randomized controlled trials since 1997 that utilized systemic cytotoxic chemotherapy agents in the systemic treatment for advanced HCC using Scopus, PubMed, and Cochrane library up to February 2020. Six randomized trials were found. Different drugs and dosages were used, so it was statistically inappropriate to conduct a meta-analysis. No Phase III trial showed statistically significant overall survival (OS) benefit for cytotoxic chemotherapy, except subgroup analysis of Chinese patients in one study who had leucovorin, fluorouracil, and oxaliplatin (FOLFOX) regimen. There was no significant progression-free survival (PFS) or response rate in the Phase II trials. There are not enough data to infer the actual benefits of systemic cytotoxic chemotherapy in advanced HCC. However, oxaliplatin-based regimens may give feasible results. Health systems with limited access to targeted therapy and immunotherapy agents may use oxaliplatin-based regimens in clinical trials for advanced HCC. These results should be confirmed in multiple future randomized clinical trials. Dove 2020-11-27 /pmc/articles/PMC7707432/ /pubmed/33273860 http://dx.doi.org/10.2147/CMAR.S280631 Text en © 2020 Abouelezz et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Review Abouelezz, Khaled Khanapara, Dipen Batiha, Gaber El-Saber Ahmed, Esraa A Hetta, Helal F Cytotoxic Chemotherapy as an Alternative for Systemic Treatment of Advanced Hepatocellular Carcinoma in Developing Countries |
title | Cytotoxic Chemotherapy as an Alternative for Systemic Treatment of Advanced Hepatocellular Carcinoma in Developing Countries |
title_full | Cytotoxic Chemotherapy as an Alternative for Systemic Treatment of Advanced Hepatocellular Carcinoma in Developing Countries |
title_fullStr | Cytotoxic Chemotherapy as an Alternative for Systemic Treatment of Advanced Hepatocellular Carcinoma in Developing Countries |
title_full_unstemmed | Cytotoxic Chemotherapy as an Alternative for Systemic Treatment of Advanced Hepatocellular Carcinoma in Developing Countries |
title_short | Cytotoxic Chemotherapy as an Alternative for Systemic Treatment of Advanced Hepatocellular Carcinoma in Developing Countries |
title_sort | cytotoxic chemotherapy as an alternative for systemic treatment of advanced hepatocellular carcinoma in developing countries |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7707432/ https://www.ncbi.nlm.nih.gov/pubmed/33273860 http://dx.doi.org/10.2147/CMAR.S280631 |
work_keys_str_mv | AT abouelezzkhaled cytotoxicchemotherapyasanalternativeforsystemictreatmentofadvancedhepatocellularcarcinomaindevelopingcountries AT khanaparadipen cytotoxicchemotherapyasanalternativeforsystemictreatmentofadvancedhepatocellularcarcinomaindevelopingcountries AT batihagaberelsaber cytotoxicchemotherapyasanalternativeforsystemictreatmentofadvancedhepatocellularcarcinomaindevelopingcountries AT ahmedesraaa cytotoxicchemotherapyasanalternativeforsystemictreatmentofadvancedhepatocellularcarcinomaindevelopingcountries AT hettahelalf cytotoxicchemotherapyasanalternativeforsystemictreatmentofadvancedhepatocellularcarcinomaindevelopingcountries |